Resolvin D1 (RvD1): A Key Lipid Mediator in the Inflammation Resolution Pathway
Inflammation is an innate immune response of the body to injury and pathogen invasion. A complete inflammatory response consists of three sequential phases: initiation, amplification, and active resolution. Conventional anti-inflammatory strategies mainly focus on suppressing inflammatory activation. Nevertheless, accumulating research in recent years has confirmed that the human body can actively regulate the outcome of inflammation via endogenous lipid mediators, among which Resolvin D1 (RvD1) stands out as a representative functional molecule in this regulatory pathway.
1. Biosynthetic Origin of RvD1
As a member of the D-series resolvins, RvD1 is biosynthesized from docosahexaenoic acid (DHA), an omega-3 polyunsaturated fatty acid. Within the inflammatory microenvironment, neutrophils, macrophages, endothelial cells and other cell types catalyze free DHA into RvD1 through a cascade of enzymatic reactions mediated by 5-lipoxygenase, 15-lipoxygenase and other enzymes. Its biosynthesis predominantly takes place in the mid-to-late stage of inflammatory responses, serving as a critical signaling molecule that triggers the body’s inflammation resolution program.
2. Core Biological Functions and Mechanisms of Action
Distinct from classical anti-inflammatory factors, RvD1’s primary function is to drive active inflammation resolution rather than merely block the onset of inflammation, and its mechanisms of action are highly target-specific:
Regulation of immune cell migration
It inhibits the chemotaxis, adhesion and infiltration of neutrophils into inflammatory lesions, alleviating secondary tissue damage induced by excessive recruitment of innate immune cells.
Mediation of efferocytosis
RvD1 activates the phagocytic capacity of macrophages to efficiently clear apoptotic cells and cellular debris in inflamed regions, halting sustained amplification of inflammatory signals and restoring homeostasis of the local microenvironment.
Modulation of cytokine secretion
It downregulates the expression of pro-inflammatory cytokines including TNF-α, IL-1β and IL-6, while elevating the levels of anti-inflammatory cytokines, thereby reversing the imbalance between pro- and anti-inflammatory factors at local sites.
3. Major Research and Application Fields
Owing to the above biological activities, RvD1 is widely investigated in basic research on various inflammation-associated diseases:
Respiratory inflammatory disorders
In preclinical models of acute lung injury, bronchial asthma and chronic obstructive pulmonary disease (COPD), RvD1 alleviates inflammatory infiltration in the airway, suppresses excessive airway mucus secretion, and slows the progression of airway remodeling.
Cardiovascular diseases
Chronic vascular inflammation constitutes a vital pathological basis for atherosclerosis and myocardial ischemia-reperfusion injury. RvD1 suppresses vascular endothelial activation, reduces monocyte adhesion and intimal infiltration, delays atherosclerotic plaque formation, and enhances plaque stability.
Central nervous system inflammation
Capable of crossing the blood-brain barrier, RvD1 inhibits aberrant microglial activation and reduces the release of neurotoxic pro-inflammatory factors, exerting neuroprotective effects in models of neurodegenerative diseases, neuropathic pain and brain injury.
Metabolic inflammation
Obesity and type 2 diabetes are accompanied by low-grade systemic chronic inflammation. RvD1 ameliorates inflammatory status in adipose tissue, improves insulin resistance, and rectifies disorders of glucose and lipid metabolism.
4. Detection Significance and Research Applications
The endogenous expression level of RvD1 directly reflects the body’s capacity for inflammation resolution. Markedly reduced RvD1 concentrations are commonly detected in samples from models of chronic inflammation, persistent tissue injury and corresponding clinical diseases, which prevents proper termination of inflammatory responses.
At present, enzyme-linked immunosorbent assay (ELISA) is the mainstream technique for quantitative measurement of RvD1 protein concentrations in biological specimens such as serum, plasma, cell culture supernatants and tissue homogenates. This detection method can be applied to: evaluating the regulatory efficacy of diverse interventions on the inflammation resolution pathway, analyzing the correlation between disease progression and RvD1 expression, and validating drug molecular targets. It provides quantitative experimental evidence for mechanistic elucidation of inflammatory disorders and the development of candidate therapeutic agents.
5. Summary of Current Research Progress
The mechanisms of action and pharmacological activities of RvD1 have been thoroughly validated in cellular and animal models, rendering it a highly promising research target in inflammation biology. However, formulations targeting this molecule remain confined to basic and preclinical research, with no clinical applications available to date. Omega-3 fatty acid supplementation provides precursor substrates for RvD1 synthesis, yet the in vivo conversion efficiency is governed by multiple variables including enzymatic activity, inflammatory status and individual metabolic profiles; thus, omega-3 supplementation cannot be regarded as a direct therapeutic intervention for inflammatory diseases.
1. Biosynthetic Origin of RvD1
As a member of the D-series resolvins, RvD1 is biosynthesized from docosahexaenoic acid (DHA), an omega-3 polyunsaturated fatty acid. Within the inflammatory microenvironment, neutrophils, macrophages, endothelial cells and other cell types catalyze free DHA into RvD1 through a cascade of enzymatic reactions mediated by 5-lipoxygenase, 15-lipoxygenase and other enzymes. Its biosynthesis predominantly takes place in the mid-to-late stage of inflammatory responses, serving as a critical signaling molecule that triggers the body’s inflammation resolution program.
2. Core Biological Functions and Mechanisms of Action
Distinct from classical anti-inflammatory factors, RvD1’s primary function is to drive active inflammation resolution rather than merely block the onset of inflammation, and its mechanisms of action are highly target-specific:
Regulation of immune cell migration
It inhibits the chemotaxis, adhesion and infiltration of neutrophils into inflammatory lesions, alleviating secondary tissue damage induced by excessive recruitment of innate immune cells.
Mediation of efferocytosis
RvD1 activates the phagocytic capacity of macrophages to efficiently clear apoptotic cells and cellular debris in inflamed regions, halting sustained amplification of inflammatory signals and restoring homeostasis of the local microenvironment.
Modulation of cytokine secretion
It downregulates the expression of pro-inflammatory cytokines including TNF-α, IL-1β and IL-6, while elevating the levels of anti-inflammatory cytokines, thereby reversing the imbalance between pro- and anti-inflammatory factors at local sites.
3. Major Research and Application Fields
Owing to the above biological activities, RvD1 is widely investigated in basic research on various inflammation-associated diseases:
Respiratory inflammatory disorders
In preclinical models of acute lung injury, bronchial asthma and chronic obstructive pulmonary disease (COPD), RvD1 alleviates inflammatory infiltration in the airway, suppresses excessive airway mucus secretion, and slows the progression of airway remodeling.
Cardiovascular diseases
Chronic vascular inflammation constitutes a vital pathological basis for atherosclerosis and myocardial ischemia-reperfusion injury. RvD1 suppresses vascular endothelial activation, reduces monocyte adhesion and intimal infiltration, delays atherosclerotic plaque formation, and enhances plaque stability.
Central nervous system inflammation
Capable of crossing the blood-brain barrier, RvD1 inhibits aberrant microglial activation and reduces the release of neurotoxic pro-inflammatory factors, exerting neuroprotective effects in models of neurodegenerative diseases, neuropathic pain and brain injury.
Metabolic inflammation
Obesity and type 2 diabetes are accompanied by low-grade systemic chronic inflammation. RvD1 ameliorates inflammatory status in adipose tissue, improves insulin resistance, and rectifies disorders of glucose and lipid metabolism.
4. Detection Significance and Research Applications
The endogenous expression level of RvD1 directly reflects the body’s capacity for inflammation resolution. Markedly reduced RvD1 concentrations are commonly detected in samples from models of chronic inflammation, persistent tissue injury and corresponding clinical diseases, which prevents proper termination of inflammatory responses.
At present, enzyme-linked immunosorbent assay (ELISA) is the mainstream technique for quantitative measurement of RvD1 protein concentrations in biological specimens such as serum, plasma, cell culture supernatants and tissue homogenates. This detection method can be applied to: evaluating the regulatory efficacy of diverse interventions on the inflammation resolution pathway, analyzing the correlation between disease progression and RvD1 expression, and validating drug molecular targets. It provides quantitative experimental evidence for mechanistic elucidation of inflammatory disorders and the development of candidate therapeutic agents.
5. Summary of Current Research Progress
The mechanisms of action and pharmacological activities of RvD1 have been thoroughly validated in cellular and animal models, rendering it a highly promising research target in inflammation biology. However, formulations targeting this molecule remain confined to basic and preclinical research, with no clinical applications available to date. Omega-3 fatty acid supplementation provides precursor substrates for RvD1 synthesis, yet the in vivo conversion efficiency is governed by multiple variables including enzymatic activity, inflammatory status and individual metabolic profiles; thus, omega-3 supplementation cannot be regarded as a direct therapeutic intervention for inflammatory diseases.
